Author

J. Zawacka-Pankau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:perturbation response prediction· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

P. Acedo· 3 shared A. Inga· 2 shared A. Fernandes· 1 shared A. Karlen· 1 shared A. Kawiak· 1 shared A. Kostecka· 1 shared A. L. Okorokov· 1 shared A. Sznarkowska· 1 shared

Activity by Year

2017-2019 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. Acedo

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukaemia cells

L. Jiang, N. Malik, P. Acedo, J. Zawacka-Pankau

This study shows that Protoporphyrin IX inhibits p53/MDM2 and p53/MDM4 interactions, stabilizes p53 and TAp73, and induces apoptosis in B-cell chronic lymphocytic leukaemia cells without harming normal cells.

bioRxiv · Feb 13, 2019Cancer Biology

Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy

J. Zawacka-Pankau, V. V. Grinkevich, M. Burmakin, A. Vema, K. Fawkner, N. Issaeva, V. Andreotti, E. R. Dickinson, E. Hedstrom, C. Spinnler, A. Inga, L.-G. Larsson, A. Karlen, O. Tarasova, V. Poroikov, , G. Selivanova

This study identifies a novel allosteric mechanism by which small molecules activate p53 by blocking MDM2/MDMX binding, offering a new approach for anticancer therapy.

bioRxiv · Dec 7, 2018 · PreprintCancer Biology

Activation of TAp73 and inhibition of thioredoxin reductase for improved cancer therapy in TP53 mutant pancreatic tumors

P. Acedo, A. Fernandes, J. Zawacka-Pankau

This paper identifies PpIX and BPD as compounds that activate TAp73 and inhibit TrxR1, inducing apoptosis in pancreatic cancer cells through a drug-repurposing approach.

bioRxiv · Sep 4, 2018Cancer Biology

Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells

A. Sznarkowska, A. Kostecka, A. Kawiak, P. Acedo, M. Lion, A. Inga, J. Zawacka-Pankau

The paper shows that protoporphyrin IX stabilizes and activates TAp73, inducing apoptosis in TP53-deficient cancer cells by disrupting interactions with MDM2/MDMX and inhibiting degradation by Itch.

bioRxiv · Aug 15, 2018Cancer Biology

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Q. Zhang, V. J. N. Bykov, K. G. Wiman, J. Zawacka-Pankau

This study identifies cysteine residues 124 and 277 as key targets of APR-246 for reactivating mutant p53 and restoring its tumor suppressor function in cancer cells.

bioRxiv · Nov 5, 2017Cancer Biology